$4.50
3.64% yesterday
Nasdaq, Oct 17, 10:00 pm CET
ISIN
US34962G1094
Symbol
FBRX
Sector
Industry

Forte Biosciences Inc Stock price

$4.50
-2.59 36.53% 1M
-14.00 75.68% 6M
-16.04 78.09% YTD
-9.48 67.80% 1Y
-63.00 93.33% 3Y
-218.85 97.99% 5Y
-4,664.25 99.90% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
-0.17 3.64%
ISIN
US34962G1094
Symbol
FBRX
Sector
Industry

Key metrics

Market capitalization $6.57m
Enterprise Value $-17.93m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.58
P/B ratio (TTM) P/B ratio 0.39
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-37.22m
Free Cash Flow (TTM) Free Cash Flow $-30.72m
Cash position $24.50m
EPS (TTM) EPS $-21.42
P/E forward negative
Short interest 0.24%
Show more

Is Forte Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Forte Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Forte Biosciences Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Forte Biosciences Inc forecast:

Buy
100%

Financial data from Forte Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.03 0.03
-
-
-0.03 -0.03
-
-
- Selling and Administrative Expenses 17 17
102% 102%
-
- Research and Development Expense 20 20
27% 27%
-
-37 -37
53% 53%
-
- Depreciation and Amortization 0.03 0.03
-
-
EBIT (Operating Income) EBIT -37 -37
53% 53%
-
Net Profit -36 -36
49% 49%
-

In millions USD.

Don't miss a Thing! We will send you all news about Forte Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Forte Biosciences Inc Stock News

Neutral
Business Wire
5 months ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors ap...
Neutral
Business Wire
7 months ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. 2023 Business Highlights “Forte achieved a major milestone by advancing FB-102 into the clinic and beating the timelines we targeted in our third qu...
Neutral
Business Wire
11 months ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of an equity award t...
More Forte Biosciences Inc News

Company Profile

Forte Biosciences, Inc. engages in the development of biopharmaceutical products. It is a clinical stage dermatology company focuses in the treatment of inflammatory skin diseases. It offers FB-401, a live bio-therapeutic product. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA.

Head office United States
CEO Paul Wagner
Employees 9
Founded 2017
Website www.fortebiorx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today